Somewhere between the 2am Google search and the clinic's glossy brochure, you heard the words "stem cell therapy." Maybe a friend swore by it. Maybe an ad promised it could help with your condition. Nobody stopped to explain what a stem cell actually is, what the different types do, or why the same two words can describe both a 70-year-old proven treatment and an unregulated injection sold for thousands.

You deserved a straight answer a long time ago.

Every cell in your body contains the same DNA. What makes a liver cell different from a neuron is not the instructions it carries but which instructions it uses. Stem cells are defined by two properties that most other cells in your adult body do not have: they can copy themselves indefinitely, and they can become other, more specialised cell types. That capacity, called differentiation, is why the field exists. And it is why the word "stem cell" carries so much weight.

The problem is that "stem cell" describes a category, not a thing. There are several meaningfully different types, and they are not interchangeable.

Haematopoietic stem cells live in your bone marrow and produce blood. They have been studied since the 1950s, transplanted in humans since 1956, and used to treat blood cancers and disorders in hundreds of thousands of patients. The evidence base is extensive. The outcomes data is real. This is the part of the stem cell world that has fully earned the trust placed in it.

Mesenchymal stem cells, or MSCs, are a different story. Found in fat tissue, bone marrow, umbilical cord tissue from newborns, and elsewhere, they have attracted enormous commercial interest over the past two decades. Umbilical cord-derived MSCs are increasingly common in clinic marketing, often described as younger or more potent than those drawn from adult tissue. The evidence for that claim is not established. They are easier to harvest and grow in a lab than haematopoietic cells, which makes them easier to sell. The clinical evidence for most of the conditions they are marketed for is thin. In many cases it is absent. The term "MSC therapy" now covers such a wide range of products and practices that it has become almost meaningless as a clinical category. Calling something "MSC treatment" tells you almost nothing about what is actually being proposed.

Induced pluripotent stem cells, or iPSCs, are the genuinely exciting development of the past twenty years. In 2006, Japanese researcher Shinya Yamanaka showed that ordinary adult cells could be reprogrammed back into a stem-cell-like state. The implications are real: patient-specific tissues grown in a lab, disease models for drug testing, potentially cell therapies with no rejection risk. Yamanaka received the Nobel Prize for this work in 2012. No iPSC-based treatments are yet approved in most countries, though early clinical trials are underway in conditions including Parkinson's disease and macular degeneration.

A study showing that a particular stem cell does something promising in a lab dish, or even in a mouse model, is not a treatment offer. It is a hypothesis, and the distance between that hypothesis and a clinical claim is routinely underplayed. The average time from a promising preclinical result to an approved therapy, when things go well, is measured in decades.

That gap is routinely papered over by hopeful headlines, clinic marketing, and occasionally by researchers who get too close to their own results.

None of this means the field is fraudulent. It means that one word is doing too much work, and that the people standing to benefit from that ambiguity are not the patients.

Registry data, Center for International Blood and Marrow Transplant Research (CIBMTR) — ongoing, multi-decade

The CIBMTR maintains outcome data from over 500,000 haematopoietic stem cell transplants performed across more than 500 centres worldwide. For certain blood cancers, including acute myeloid leukaemia, five-year survival rates following transplant have climbed from under 40% in the 1970s to over 60% in recent cohorts.

Study type: Registry data, human patients

Evidence level: Large-scale, multi-decade, independently verified

Key caveat: Outcomes vary by condition, patient age, donor match, and transplant centre. Transplantation carries real risks, including graft-versus-host disease in allogeneic cases.

This is included not because it is new but because it is the benchmark. These results took decades of clinical trials, failures, and refinements to produce. When someone tells you stem cell therapy has been proven to work, this is the evidence they should be pointing to - and in most commercial contexts, it is not what they are pointing to.

These come up constantly in stem cell discussions and they are worth understanding.

Autologous means the cells used in treatment come from the patient's own body. Harvested, sometimes processed or grown in a lab, then returned. Clinics often present this as inherently safe because your own cells cannot trigger an immune rejection response.

Allogeneic means the cells come from a donor. Rejection is a genuine risk, which is why allogeneic treatments require careful matching and ongoing monitoring. Bone marrow transplantation is almost always allogeneic.

The important correction: autologous does not mean safe. Contamination during processing, incorrect dosing, and injecting cells into inappropriate anatomical locations are all risks that have nothing to do with immune rejection. "Your own cells" is a starting point, not a guarantee.

The term "stem cell" was coined in 1868 by German biologist Ernst Haeckel. He meant it precisely: a progenitor cell that gives rise to others. It took roughly 150 years for it to end up on a wellness clinic menu.